COMMUNIQUÉS West-GlobeNewswire

Actimed Therapeutics Appoints Shaun Claydon as Chief Financial Officer
24/04/2025
London, UK – 24 th April 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
24/04/2025
Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations underway to initiate [...]
Bioxodes annonce des données intermédiaires positives pour son essai de phase 2a portant sur BIOX-101 dans le traitement de l’AVC hémorragique
24/04/2025
Le critère d’évaluation principal a été atteint, aucun événement indésirable grave associé au médicament n’a été rapporté L’évolution du volume de l’hématome et de l’œdème est favorable Le recrutement des patients a été [...]
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
24/04/2025
Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options Patients treated [...]
Les dernières données sur l’élafibranor démontrent un profil de tolérance favorable et une efficacité significative dans la CSP, une deuxième indication dans les maladies rares du foie
24/04/2025
L’élafibranor a montré un profil de tolérance favorable et a démontré une efficacité en termes de relation dose-effet sur 12 semaines chez des patients atteints de CSP, une maladie rare du foie pour laquelle il n’existe [...]
Pharming Group to report first quarter 2025 financial results on May 8
24/04/2025
Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period [...]
ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX Best Market
24/04/2025
Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch BNY will be ADR depositary bank Ticker symbol for US investors is ONWRY EINDHOVEN, the Netherlands, [...]
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
24/04/2025
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO [...]
Communiqué de presse : Sanofi : forte performance au T1 et confirmation des perspectives pour 2025
24/04/2025
Sanofi : forte performance au T1 et confirmation des perspectives pour 2025 Paris, le 24 avril 2025 Ventes du T1 en progression de 9,7 % à TCC 1 et BNPA 2 des activités de 1,79 euro Les ventes des nouveaux lancements [...]
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
24/04/2025
Allschwil, Switzerland, April 24, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
24/04/2025
Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUPREME-2 trial [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter
24/04/2025
Group sales grew by 6% 1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions. Pharmaceuticals Division sales rose by 8% (9% in CHF) on continued strong demand [...]
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
24/04/2025
Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological [...]
Merus annonce l’acceptation de son résumé pour présentation au congrès annuel 2025 de l’ASCO®
24/04/2025
- Le pétosemtamab en association avec le pembrolizumab en traitement de première intention d'un CETC r/m PD-L1+ : premières données cliniques provisoires sélectionnées pour une présentation sous forme d’affiche - [...]
Test Your Poison Launches Drug Testing Kits to Improve Public Safety and Address Drug Contamination Risks at Festivals and Nightclubs
24/04/2025
New drug testing kits help festival goers detect dangerous substances, promoting safer choices and harm reduction Test Your Poison Logo LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Test Your Poison, a leader in harm [...]
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
24/04/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of [...]
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
24/04/2025
ROCKVILLE, Md. and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to [...]
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
23/04/2025
– Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression – – Detailed [...]
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
23/04/2025
ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]

Pages